Skip to main content
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1991 Aug;35(8):1547–1550. doi: 10.1128/aac.35.8.1547

Development of resistance to fleroxacin during therapy of experimental methicillin-susceptible Staphylococcus aureus endocarditis.

G W Kaatz 1, S M Seo 1, S L Barriere 1, L M Albrecht 1, M J Rybak 1
PMCID: PMC245216  PMID: 1929325

Abstract

The efficacy of fleroxacin was compared with that of vancomycin by using the rabbit model of methicillin-susceptible Staphylococcus aureus endocarditis. Animals received intravenous therapy with fleroxacin, 30 mg/kg every 8 h, or vancomycin, 17.5 mg/kg every 6 h, for 4 days. Both antimicrobial agents effectively cleared bacteremia and significantly reduced bacterial counts in vegetations and tissues compared with those in untreated controls. However, resistance to fleroxacin at 5- and 10-fold the MIC arose in the test strain of S. aureus in 73 and 27%, respectively, of animals that received the drug. Resistant isolates were found mainly in vegetations and were composed of up to 7% of the residual population recovered from that site. We conclude that fleroxacin is as effective as vancomycin in this model of a serious systemic S. aureus infection, but resistance to the drug may develop during therapy. If similar results are found with other strains of S. aureus during therapy with this or other fluoroquinolones, such data, when they are combined with the high incidence of fluoroquinolone resistance among S. aureus isolates being reported from selected institutions, would support the contention that these drugs should not be used as first-line therapeutic agents for S. aureus infections.

Full text

PDF
1547

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Chin N. X., Brittain D. C., Neu H. C. In vitro activity of Ro 23-6240, a new fluorinated 4-quinolone. Antimicrob Agents Chemother. 1986 Apr;29(4):675–680. doi: 10.1128/aac.29.4.675. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Gilbert M., Boscia J. A., Kobasa W. D., Kaye D. Enoxacin compared with vancomycin for the treatment of experimental methicillin-resistant Staphylococcus aureus endocarditis. Antimicrob Agents Chemother. 1986 Mar;29(3):461–463. doi: 10.1128/aac.29.3.461. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Humphreys H., Mulvihill E. Ciprofloxacin-resistant Staphylococcus aureus. Lancet. 1985 Aug 17;2(8451):383–383. doi: 10.1016/s0140-6736(85)92510-3. [DOI] [PubMed] [Google Scholar]
  4. Kaatz G. W., Barriere S. L., Schaberg D. R., Fekety R. Ciprofloxacin versus vancomycin in the therapy of experimental methicillin-resistant Staphylococcus aureus endocarditis. Antimicrob Agents Chemother. 1987 Apr;31(4):527–530. doi: 10.1128/aac.31.4.527. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Kaatz G. W., Barriere S. L., Schaberg D. R., Fekety R. The emergence of resistance to ciprofloxacin during treatment of experimental Staphylococcus aureus endocarditis. J Antimicrob Chemother. 1987 Nov;20(5):753–758. doi: 10.1093/jac/20.5.753. [DOI] [PubMed] [Google Scholar]
  6. Kaatz G. W., Seo S. M., Barriere S. L., Albrecht L. M., Rybak M. J. Efficacy of fleroxacin in experimental methicillin-resistant Staphylococcus aureus endocarditis. Antimicrob Agents Chemother. 1989 Apr;33(4):519–521. doi: 10.1128/aac.33.4.519. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Kaatz G. W., Seo S. M., Barriere S. L., Albrecht L. M., Rybak M. J. Efficacy of ofloxacin in experimental Staphylococcus aureus endocarditis. Antimicrob Agents Chemother. 1990 Feb;34(2):257–260. doi: 10.1128/aac.34.2.257. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Kaatz G. W., Seo S. M., Ruble C. A. Mechanisms of fluoroquinolone resistance in Staphylococcus aureus. J Infect Dis. 1991 May;163(5):1080–1086. doi: 10.1093/infdis/163.5.1080. [DOI] [PubMed] [Google Scholar]
  9. Panneton A. C., Bergeron M. G., LeBel M. Pharmacokinetics and tissue penetration of fleroxacin after single and multiple 400- and 800-mg-dosage regimens. Antimicrob Agents Chemother. 1988 Oct;32(10):1515–1520. doi: 10.1128/aac.32.10.1515. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Peterson L. R., Quick J. N., Jensen B., Homann S., Johnson S., Tenquist J., Shanholtzer C., Petzel R. A., Sinn L., Gerding D. N. Emergence of ciprofloxacin resistance in nosocomial methicillin-resistant Staphylococcus aureus isolates. Resistance during ciprofloxacin plus rifampin therapy for methicillin-resistant S aureus colonization. Arch Intern Med. 1990 Oct;150(10):2151–2155. [PubMed] [Google Scholar]
  11. Pohlod D. J., Saravolatz L. D., Somerville M. M. In-vitro susceptibility of staphylococci to fleroxacin in comparison with six other quinolones. J Antimicrob Chemother. 1988 Oct;22 (Suppl 500):35–41. doi: 10.1093/jac/22.supplement_d.35. [DOI] [PubMed] [Google Scholar]
  12. Schaefler S. Methicillin-resistant strains of Staphylococcus aureus resistant to quinolones. J Clin Microbiol. 1989 Feb;27(2):335–336. doi: 10.1128/jcm.27.2.335-336.1989. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Schwalbe R. S., Stapleton J. T., Gilligan P. H. Emergence of vancomycin resistance in coagulase-negative staphylococci. N Engl J Med. 1987 Apr 9;316(15):927–931. doi: 10.1056/NEJM198704093161507. [DOI] [PubMed] [Google Scholar]
  14. Schwenzer K. S., Wang C. H., Anhalt J. P. Automated fluorescence polarization immunoassay for monitoring vancomycin. Ther Drug Monit. 1983;5(3):341–345. doi: 10.1097/00007691-198309000-00017. [DOI] [PubMed] [Google Scholar]
  15. Shalit I., Berger S. A., Gorea A., Frimerman H. Widespread quinolone resistance among methicillin-resistant Staphylococcus aureus isolates in a general hospital. Antimicrob Agents Chemother. 1989 Apr;33(4):593–594. doi: 10.1128/aac.33.4.593. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Sullam P. M., Täuber M. G., Hackbarth C. J., Chambers H. F., Scott K. G., Sande M. A. Pefloxacin therapy for experimental endocarditis caused by methicillin-susceptible or methicillin-resistant strains of Staphylococcus aureus. Antimicrob Agents Chemother. 1985 May;27(5):685–687. doi: 10.1128/aac.27.5.685. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES